Penfigóide Bolhoso Refractário em Paciente Infectado pelo Vírus da Imunodeficiência Humana
Resumo
Penfigóide bolhoso, a dermatose bolhosa subepidérmica auto-imune mais comum, é devida a auto-anticorpos contra partículas dos hemidesmosmas (BP180 e/ou BP230) e caracteriza-se por prurido e bolhas cutâneas tensas sobre base eritematosa ou pele normal. Afeta predominantemente idosos, por vezes com comorbilidades neurológicas ou neopláscias. A associação a infecção pelo vírus da imunodeficiência humana é rara. Relatamos o caso de uma paciente jovem VIH+ em tratamento antirretroviral com carga viral indetectável e contagem normal de células T CD4+, que desenvolveu penfigóide bolhoso com lesões extensas, incluindo na mucosa oral, resistentes a vários pulsos de corticoides, corticoides orais e metotrexato, com melhora e estabilidade clínica apenas após uma infusão de rituximab, um anticorpo monoclonal anti-CD20.
Downloads
Referências
ReferênciasTarazona MJM, Unterstell N, Mota da Silva AN, Bressan AL, Gripp AC. Penfigoide bolhoso e doença neurológica: casuística de um Serviço de Dermatologia. An Bras Dermatol. 2015; 90: 282-4.
Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012; 45: 55-70.
Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol. 2001; 117: 1091-6.
Donoso-Hofer F. Lesiones orales asociadas con la enfermedad del virus de immunodeficiencia humana en pacientes adultos, una perspectiva clínica. Rev Chilena Infectol. 2016; 33 (Suppl 1): 27-35.
Dipankar De, Amrinder JK, Bishan DR, Tarun N. Bullous eruption in a patient infected with the human immunodeficiency virus. Skinmed. 2008:7; 98-101.
Stahl D, Lacroix-Desmazes S, Misra N, Karmochkine M, Kaveri SV, Costagliola D, et al. Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells. Immunol Lett. 2005; 99: 198-208.
Tsiakalos A, Routsias JG, Kordossis T, Moutsopoulos HM, Tzioufas AG, Sipsas NV. Fine epitope specificity of anti-erythropoietin antibodies reveals molecular mimicry with HIV-1 p17 protein: a pathogenetic mechanism for HIV-1 related anemia. J Infect Dis. 2011; 204: 902-11.
Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity. 1994; 18: 205-11.
Iordache L, Launay O, Bouchaud O, Jeantils V, Goujard C, Boue F, et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun Rev. 2014; 13:850-7.
Lateef A, Packles MR, White SM, Don PC, Weinberg JM. Pemphigus vegetans in association with human immunodeficiency virus. Int J Dermatol. 1999; 38: 778-81.
Cruz MJ, Santos P, Morais P, Barreto F, Azevedo F. Refractory bullous pemphigoid with fatal outcome in a Young patient. Int J Dermatol. 2013; 52: 601-2.
Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D,et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration
with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015; 172: 867-77.
Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002; 346:321–7.
Cabete J, Fidalgo A, Páris FR, Santos G, Serrão V. Intravenous immunoglobulin for the treatment of quetiapin-induced bullous pemphigoid in an HIV-infected patient. J Am Acad Dermatol. 2013: AB113.
Joly P, Mouquet H, Roujeau JC, D’Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007; 357: 545-52.
Bomm L, Sodré JL, Fracaroli TS, Bressan AL, Gripp AC. Uso off label do rituximab na dermatologia: tratamento dos pênfigos. An Bras Dermatol. 2013; 88: 687-9.
Shetty S, Ahmed AR. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol. 2013;12: 672-7.
Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016; 74: 700-8.
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013; 122: 3251-62.
Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hubel K. HIV-associated malignant lymphoma. Oncol Res Treat. 2017; 40: 82-87.
Todos os artigos desta revista são de acesso aberto sob a licença internacional Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0).